Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

Wednesday's "Earnings Beat" Makes This The Perfect "Bad-Market" Tech Stock

In last week’s Private Briefing report Our Experts Show You the Stocks to Pick in a ‘Stock-Picker’s Market’,” Money Map Press Chief Investment Strategist Keith Fitz-Gerald identified SanDisk Corp.(NasdaqGS: SNDK) as one of three stocks to buy in the face of the stock market sell-off.

And now we see why…

Category

Stocks Archives - Page 6 of 174 - Money Morning - Only the News You Can Profit From- Money Morning - Only the News You Can Profit From.

  • J.C. Penney (NYSE: JCP) Earnings Spark 16% Jump After Hours

    J.C. Penney Company Inc.’s (NYSE: JCP) 36-year-old tale will likely continue in tragedy today (Wednesday), as it is projected to report a $0.81 per share loss in its Q4 2013 earnings after the bell.

    That would notch a $239.15 million net loss, compared with a loss of $427 million, or $2.51 cents per share, in the same quarter last year, according to a survey of analysts by Thomson Reuters.

    To continue reading, please click here...

  • Why First Solar (Nasdaq: FSLR) Stock Is Among Today's Biggest Losers

    First Solar Inc. (Nasdaq: FSLR) stock is down 12% today (Wednesday) after reporting Q4 adjusted earnings of $0.89 per share on revenue of $768 million. Analysts surveyed by FactSet had projected earnings per share (EPS) of $0.98 on revenue of $973 million.

    The adjusted earnings added $0.25 per share related to a recent agreement for First Solar to sell its facility in Mesa, Ariz. Generally accepted accounting principles (GAAP) earnings were $0.64 per share, which was down from $1.74 the year before.

    Revenue for the full year 2013 was $3.31 billion – down 1.8% from 2012. Analysts at Zacks Investment Research had projected yearly revenue of $3.53 billion.

  • Why Target Corp. (NYSE: TGT) Is a Buy, Despite Bad Earnings

    Target Corp. (NYSE: TGT) will report Q4 2013 earnings Wednesday morning. Look for two recent events to depress TGT's numbers – which means if markets react negatively, investors can buy this solid retailer at a discount.

    Wall Street expects Target Corp. to report fourth-quarter earnings per share (EPS) of $0.80 on revenue of $21.46 billion, up $0.56 from the previous period, but down from $1.47 on revenue of $22.73 billion when compared to a year ago in the same period.

    To continue reading, please click here...

  • Best Stocks to Buy Now: How to Play 2014's Most Profitable Trends Today

    Best Investments for the week ending Feb. 21, 2014: U.S. stocks slipped last week as markets reacted to a string of disappointing data from housing to manufacturing.

    For the week, the Dow Jones Industrial Average dipped 0.3% to close at 16,103.30. The S&P 500 Index lost 0.1% to end at 1,836.25. The Nasdaq tacked on 0.5% to end at 4,263.41.

    Following is a recap from last week...

  • Groupon (Nasdaq: GRPN) Earnings Update: Record-Breaking Quarter, and Promising Future on these Two Numbers

    Groupon Inc. (Nasdaq: GRPN) will report Q4 2013 earnings after closing bell today (Thursday). GRPN stock gained 1.2% in pre-market trading Thursday, despite projections of a slow quarter.

    The current Wall Street consensus expectation is earnings per share (EPS) gain of $0.02 per share on $718.67 million in revenue, compared to a loss of $0.01 per share in the same period a year ago.

    To continue reading, please click here...

  • Wal-Mart Stores Inc. (NYSE: WMT) Earnings Preview: Whether a Hit or a Miss, Don't Buy

    WAL-MART STORES
    NYSE: WMT
    Apr 17
    loading chart...
    Price: 77.66 | Ch: 0.44 (0.6%)

    Thursday, Wal-Mart Stores Inc. (NYSE: WMT) will report fourth-quarter earnings before opening bell. A challenging retail environment and recent restructuring are likely to keep Wal-Mart from beating – or even meeting – expectations.

    That's just one reason investors should steer clear of Wal-Mart stock.

    The retail superstore has missed Wall Street expectations in three of the last eight quarters and averages a 1% stock loss in the week following earnings.

    This time around, it is expected to report fourth-quarter earnings per share (EPS) of $1.37 on revenue of $130.55 billion, compared with a profit of $1.67 per share on revenue of $127.92 billion in the same quarter a year ago.

    To continue reading, please click here...

  • Best Stocks to Buy: How to Play 2014's Most Lucrative Trends Now

    Best stocks to buy for the week ending Feb. 14, 2014: All three major benchmarks neared record highs last week, posting their biggest weekly gains of 2014.

    The Dow Jones Industrial Average climbed 2.3% to end the week at 16,154.39. The S&P 500 Index tacked on 2.3% to 1,838.63 – within spitting distance of its 1,848.38 record close. The Nasdaq rose 2.9% to 4,244.03, its highest level in 13.5 years.

    But the best gains came from precious metals. Concerns about a flagging U.S. economy ignited renewed interest in gold and silver as reluctantly bullish investors hedged their bets.

    To continue reading, please click here...

  • Tesla Motors (Nasdaq: TSLA) Stock Soars on Earnings Beat

    Tesla Motors Inc. (Nasdaq: TSLA) stock reached another all-time high yesterday (Tuesday) of $205.72 ahead of today's earnings report. TSLA stock has gained 516% since the beginning of 2013 and had set a previous high of $202.20 just one week ago.

    Analysts expect earnings per share (EPS) of $0.19 for Tesla, on revenue of $663 million for Q4. That revenue estimate is a 116% increase from the same quarter last year.

    For the full year 2013, analysts project EPS of $0.63 on $2.39 billion in revenue.

    Unlike many companies who report earnings, Tesla's profit will not be the main highlight.

    This is what 2014 holds for Tesla...

  • This Patent Cliff 2014 Chart Shows How Much Revenue Big Pharma Will Lose

    More pharmaceutical companies will lose drug patents to the patent cliff in 2014, threatening billions of dollars in revenue for Big Pharma.

    Patent Cliff 2014 chart

    Once a drug is off patent, other pharmaceutical companies are free to replicate the product. That can drastically slash the revenue of pharmaceutical companies that have been making billions of dollars from their patented products.

    Not all patent-cliff companies face immediate competition, but they do face huge threats to their revenue. And that can worry investors.

    Just look at this patent cliff chart illustrating how much the biggest pharmaceutical companies stand to lose:

    Patent Cliff 2014: Who Stands to Lose

    To continue reading, please click here...

  • Two Numbers Microsoft (Nasdaq: MSFT) Doesn't Want Investors to See

    Microsoft's (Nasdaq: MSFT) new CEO Satya Nadella could bring the company what it's been missing, as we recently pointed out, but Nadella will have to tackle two very troubling numbers just reported for Microsoft.

    These are figures that give us a glimpse of what could prevent MSFT stock from climbing in 2014 following its 40.9% rise last year.

    These numbers were just released last week – and they're ugly.

    Here's the story...